Align Technology's (ALGN) stock plummeted 6.35% in the 24 hours leading up to the post-market session on Wednesday. The medical device company, known for its Invisalign clear aligners, reported mixed fourth-quarter 2024 results and issued a disappointing revenue guidance for the first quarter of 2025.

For Q4 2024, Align Technology's revenue grew 4% year-over-year to $995.2 million, slightly beating analysts' estimates. However, the company's adjusted earnings per share (EPS) of $2.44 missed expectations, coming in at $1.39. The miss was primarily attributed to unfavorable foreign exchange rates and restructuring charges related to post-employment benefits.

More concerning for investors was Align Technology's revenue guidance for Q1 2025. The company expects revenue between $965 million and $985 million, falling short of analysts' consensus estimate of $1.03 billion. This guidance suggests softer demand for Align's clear aligners, particularly among teenage and younger patients.